Literature DB >> 7932078

Wild-type and mutant HIV-1 and HIV-2 Tat proteins expressed in Escherichia coli as fusions with glutathione S-transferase.

H Rhim1, C O Echetebu, C H Herrmann, A P Rice.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) and HIV-2 encode related transcriptional activators known as Tat-1 and Tat-2, respectively, that are required for efficient viral replication. The Tat proteins have been studied extensively, and it appears that their mechanism of action is unique to the primate immunodeficiency viruses or a few distantly related lentiviruses. Here we describe a collection of 24 wild-type and mutant Tat-1 and Tat-2 proteins that are expressed in Escherichia coli as fusions with glutathione S-transferase (GST). The GST-Tat fusions can be used for biochemical studies after simple purification from E. coli lysates in a single step under nondenaturing conditions. The availability of these GST-Tat fusions should be useful to investigators examining biochemical properties of Tat-1 and Tat-2 proteins. E. coli cultures harboring GST-Tat fusions described here are available through the National Institute of Health AIDS Research and Reference Reagent Program.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7932078

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  18 in total

1.  Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.

Authors:  M Kotler; M Simm; Y S Zhao; P Sova; W Chao; S F Ohnona; R Roller; C Krachmarov; M J Potash; D J Volsky
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen.

Authors:  Emmanuel Moreau; Johan Hoebeke; Daniel Zagury; Sylviane Muller; Claude Desgranges
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

3.  Isolation and functional characterization of P-TEFb-associated factors that control general and HIV-1 transcriptional elongation.

Authors:  Ruichuan Chen; Min Liu; Kai Zhang; Qiang Zhou
Journal:  Methods       Date:  2010-04-10       Impact factor: 3.608

4.  Viral transactivators E1A and VP16 interact with a large complex that is associated with CTD kinase activity and contains CDK8.

Authors:  M O Gold; J P Tassan; E A Nigg; A P Rice; C H Herrmann
Journal:  Nucleic Acids Res       Date:  1996-10-01       Impact factor: 16.971

5.  Reciprocal modulatory interaction between human immunodeficiency virus type 1 Tat and transcription factor NFAT1.

Authors:  F Macián; A Rao
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

6.  Constitutive activation of gene expression by thyroid hormone receptor results from reversal of p53-mediated repression.

Authors:  J S Qi; V Desai-Yajnik; Y Yuan; H H Samuels
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

7.  Viral transactivators specifically target distinct cellular protein kinases that phosphorylate the RNA polymerase II C-terminal domain.

Authors:  C H Herrmann; M O Gold; A P Rice
Journal:  Nucleic Acids Res       Date:  1996-02-01       Impact factor: 16.971

8.  Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor.

Authors:  C H Herrmann; A P Rice
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

9.  Human and rodent transcription elongation factor P-TEFb: interactions with human immunodeficiency virus type 1 tat and carboxy-terminal domain substrate.

Authors:  Y Ramanathan; S M Reza; T M Young; M B Mathews; T Pe'ery
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

10.  Integration of HIV-1 DNA is regulated by interplay between viral rev and cellular LEDGF/p75 proteins.

Authors:  Aviad Levin; Joseph Rosenbluh; Zvi Hayouka; Assaf Friedler; Abraham Loyter
Journal:  Mol Med       Date:  2009-10-29       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.